ES2174034T3 - Naftilglioxamidas como inhibidores de spla2 - Google Patents

Naftilglioxamidas como inhibidores de spla2

Info

Publication number
ES2174034T3
ES2174034T3 ES96308901T ES96308901T ES2174034T3 ES 2174034 T3 ES2174034 T3 ES 2174034T3 ES 96308901 T ES96308901 T ES 96308901T ES 96308901 T ES96308901 T ES 96308901T ES 2174034 T3 ES2174034 T3 ES 2174034T3
Authority
ES
Spain
Prior art keywords
naftilglioxamids
compounds
spla2 inhibitors
glicoxamide
naftilo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96308901T
Other languages
English (en)
Inventor
Theodore Goodson Jr
David Kent Herron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9602268.6A external-priority patent/GB9602268D0/en
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2174034T3 publication Critical patent/ES2174034T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE DESCRIBE UNA CLASE DE NUEVOS COMPUESTOS DE GLICOXAMIDA DE NAFTILO DE FORMULA (I) JUNTO CON UN PROCEDIMIENTO PARA FABRICAR LOS NUEVOS COMPUESTOS DE GLICOXAMIDA DE NAFTILO Y EL USO DE DICHOS COMPUESTOS PARA INHIBIR LA LIBERACION MEDIADA POR SPLA{SUB,2} DE ACIDOS GRASOS PARA TRATAMIENTO DE CONDICIONES COMO CHOQUE SEPTICO.
ES96308901T 1995-12-13 1996-12-09 Naftilglioxamidas como inhibidores de spla2 Expired - Lifetime ES2174034T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US855795P 1995-12-13 1995-12-13
GBGB9602268.6A GB9602268D0 (en) 1996-02-05 1996-02-05 Naphthyl glyoxamides as sPLA2 inhibitors

Publications (1)

Publication Number Publication Date
ES2174034T3 true ES2174034T3 (es) 2002-11-01

Family

ID=26308608

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96308901T Expired - Lifetime ES2174034T3 (es) 1995-12-13 1996-12-09 Naftilglioxamidas como inhibidores de spla2

Country Status (9)

Country Link
EP (1) EP0779273B1 (es)
JP (1) JP2000502083A (es)
KR (1) KR19990072111A (es)
AU (1) AU1149797A (es)
ES (1) ES2174034T3 (es)
HU (1) HUP9902120A3 (es)
IL (1) IL124871A (es)
MX (1) MX9804750A (es)
WO (1) WO1997021716A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3054399A (en) 1998-03-31 1999-10-25 Shionogi & Co., Ltd. Pyrrolo(1,2-a)pyrazine sPLA2 inhibitor
CN1302300A (zh) 1998-05-21 2001-07-04 盐野义制药株式会社 吡咯并[1,2－b]哒嗪sPLA2抑制剂
CA2346334A1 (en) 1998-10-14 2000-04-20 Shionogi & Co., Ltd. Composition for treating or preventing ischemia reperfusion injury
JP4636521B2 (ja) 1999-07-19 2011-02-23 塩野義製薬株式会社 ｓＰＬＡ２阻害作用を有する三環系化合物
JP4636522B2 (ja) 1999-08-02 2011-02-23 塩野義製薬株式会社 ｓＰＬＡ２阻害作用を有する三環式化合物
US6787545B1 (en) 1999-08-23 2004-09-07 Shiongi & Co., Ltd. Pyrrolotriazine derivatives having spla2-inhibitory activities
US6756376B1 (en) 1999-11-15 2004-06-29 Shionogi & Co., Ltd. Tricyclic azaindolizine derivatives having an sPLA2-inhibitory activities
AU2001267823A1 (en) 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Compounds exhibiting x-type spla2 inhibiting effect
AU2001267825A1 (en) 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Remedies for cirrhosis
TWI314457B (es) 2001-03-19 2009-09-11 Shionogi & Co

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5436369A (en) * 1993-06-16 1995-07-25 Bristol-Myers Squibb Company Alicyclic phospholipase A2 inhibitors

Also Published As

Publication number Publication date
EP0779273A1 (en) 1997-06-18
HUP9902120A3 (en) 1999-12-28
JP2000502083A (ja) 2000-02-22
IL124871A0 (en) 1999-01-26
MX9804750A (es) 1998-10-31
HUP9902120A2 (hu) 1999-11-29
WO1997021716A1 (en) 1997-06-19
AU1149797A (en) 1997-07-03
EP0779273B1 (en) 2002-03-20
KR19990072111A (ko) 1999-09-27
IL124871A (en) 2002-04-21

Similar Documents

Publication Publication Date Title
ES2179088T3 (es) Inhibidores de flsa2 1h-indol-3-glioxilamida.
EA199900301A2 (ru) Замещенные трициклические соединения
ES2159347T3 (es) Naftil-acetamidas como inhibidores de spla2.
BG101422A (bg) Бензоксазолни производни като бронхоразширяващи средства
ES2183331T3 (es) Inhibidores de sulfamida-metaloproteasa.
GT199900029A (es) Compuestos heterociclicos como inhibidores de enzimas rotamasas.
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
ES2178676T3 (es) Compuestos de pirimidina substituidos y su empleo.
ES2138691T3 (es) Procedimiento para la obtencion de derivados de n-acil-5-fluorocitidina.
AR023727A1 (es) Compuestos empleados en el tratamiento de padecimientos inflamatorios
AR009358A1 (es) Compuesto espirociclico inhibidor de la metaloproteasa
BR9713261A (pt) Tricìclicos substituìdos
ES2174034T3 (es) Naftilglioxamidas como inhibidores de spla2
ES2061559T3 (es) Triazolinonas substituidas.
ES2060818T3 (es) Derivados de indol, benzofurano y benzotiofeno sustituidos como inhibidores de la 5-lipooxigenasa.
EA199900304A2 (ru) Замещенные трициклические соединения
ES2195182T3 (es) Fenil glioxamidas como inhibidores de spla2.
DE69834271D1 (de) Steroid-3-o-sulfamat-derivate als estronsulfatase-hemmer
ES2191109T3 (es) Inhibidores de proteasas de guanidino.
ES2181052T3 (es) Fenilacetamidas como inhibidores de la spla2.
ES2145563T3 (es) Nuevos derivados de la imidazolina con una afinidad para los receptores imidazolinicos.
ECSP003590A (es) Compuestos calcioliticos
ES2191683T3 (es) Procedimiento para preparar inhibidores de la proteasa del vih.
AR021577A1 (es) Preparado con una amplitud terapeutica mejorada, que contiene inhibidores de la sintesis de los nucleotidos
DE69910432D1 (de) Substituierte pyrroloindole

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 779273

Country of ref document: ES